Folate is essential for DNA synthesis and the survival and growth of the malaria parasite. Folate sufficiency may be associated with an increased risk of malaria. Antifolate antimalarial drugs are of major importance in the prophylaxis and treatment of malaria. Folic acid reverses the inhibition by antifolate drugs of plasmodial growth or survival in vitro, and folic acid supplements given to children with malaria may increase the failure rate of treatment with antimalarials. There is no convincing evidence of a significant prevalence of folate deficiency in children in malarious areas, nor of a beneficial effect of folic acid supplementation on malarial anemia. In areas where Plasmodium falciparum malaria is holoendemic, universal supplementation of children with iron and folic acid may increase the incidence of severe morbidity and mortality. These regions should be excluded from the World Health Organization recommendation of universal folic acid supplementation of children in areas of high prevalence of anemia. This does not apply to supplementation of pregnant women with folic acid.
WHO Expert Committee on Malaria. World Health Organ Tech Rep Ser 2000;892:i-v,1–74.
2.
BairdJK. Effectiveness of antimalarial drugs. N Engl J Med2005;352:1565–77.
3.
ChanarinI. The megaloblastic anemias, 2nd ed.Oxford, UK: Blackwell Scientific, 1979.
4.
HydeJE. Exploring the folate pathway in Plasmodium falciparum. Acta Trop2005;94:191–206.
5.
WangPWangQAspinallTVSimsPFHydeJE. Transfection studies to explore essential folate metabolism and antifolate drug synergy in the human malaria parasite Plasmodium falciparum. Mol Microbiol2004;51:1425–38.
6.
KrungkraiJWebsterHKYuthavongY. De novo and salvage biosynthesis of pteroylpentaglutamates in the human malaria parasite, Plasmodium falciparum. Mol Biochem Parasitol1989;32:25–37.
7.
WatkinsWMSixsmithDGChulayJDSpencerHC. Antagonism of sulfadoxine and pyrimethamine antimalarial activity in vitro by p-aminobenzoic acid, p-aminobenzoylglutamic acid and folic acid. Mol Biochem Parasitol1985;14:55–61.
8.
MilhousWKWeatherlyNFBowdreJHDesjardinsRE. In vitro activities of and mechanisms of resistance to antifol antimalarial drugs. Antimicrob Agents Chemother1985;27:525–30.
9.
WangPReadMSimsPFHydeJE. Sulfadoxine resistance in the human malaria parasite Plasmodium falciparum is determined by mutations in dihydropteroate synthetase and an additional factor associated with folate utilization. Mol Microbiol1997;23:979–86.
10.
WangPBrobeyRKHoriiTSimsPFHydeJE. Utilization of exogenous folate in the human malaria parasite Plasmodium falciparum and its critical role in antifolate drug synergy. Mol Microbiol1999;32:1254–62.
11.
FeroneR. Folate metabolism in malaria. Bull World Health Organ1977;55:291–8.
12.
PetersW. Chemotherapy and drug resistance in malaria. 2nd ed.London: Academic Press, 1987.
13.
DasKCVirdiJSHerbertV. Survival of the dietarily deprived: Folate deficiency protects against malaria in primates. Blood1992;80(suppl 1):281a.
14.
HamiltonPJGebbieDAWilksNELotheF. The role of malaria, folic acid deficiency and haemoglobin AS in pregnancy at Mulago hospital. Trans R Soc Trop Med Hyg1972;66:594–602.
15.
HercbergSChauliacMGalanPDevanlayMZohounIAgbotonYSoustreYBoriesCChristidesJPPotier de CourcyGMasse-RaimbaultA-MDupinH. Relationship between anaemia, iron and folacin deficiency, haemoglobinopathies and parasitic infection. Hum Nutr Clin Nutr1986;40:371–9.
16.
BrabinBJ. A comparison of maternal and foetal folacin and cobalamin activities at parturition in relation to Plasmodium falciparum infection. Trans R Soc Trop Med Hyg1985;79:652–6.
17.
Bradley-MooreAMGreenwoodBMBradleyAKAkintundeAAttaiEDFlemingAFFlynnFVKirkwoodBRGillesHM. Malaria chemoprophylaxis with chloroquine in young Nigerian children. IV. Its effect on haematological measurements. Ann Trop Med Parasitol1985;79:585–95.
18.
AbdallaSH. Iron and folate status in Gambian children with malaria. Ann Trop Paediatr1990;10:265–72.
19.
van HensbroekMBMorris-JonesSMeisnerSJaffarSBayoLDackourRPhillipsCGreenwoodBM. Iron, but not folic acid, combined with effective antimalarial therapy promotes haematological recovery in African children after acute falciparum malaria. Trans R Soc Trop Med Hyg1995;89:672–6.
20.
DzinjalamalaFKMachesoAKublinJGTaylorTEBarnesKIMolyneuxMEPloweCVSmithPJ. Blood folate concentrations and in vivo sulfadoxine-pyrimethamine failure in Malawian children with uncomplicated Plasmodium falciparum malaria. Am J Trop Med Hyg2005;72:267–72.
21.
MulengaMMalungaPBennettSThumaPShulmanCFieldingKGreenwoodB. Folic acid treatment of Zambian children with moderate to severe malaria anemia. Am J Trop Med Hyg2006;74:986–90.
22.
OppenheimerSJCashinP. Serum and red cell folate levels associated with malarial parasitaemia. Trans R Soc Trop Med Hyg1986;80:169–71.
23.
TragerW. The enhanced folic and folinic acid contents of erythrocytes infected with malaria parasites. Exp Parasitol1959;8:265–73.
BrabinBJvan den BergHNijmeyerF. Folacin, cobalamin, and hematological status during pregnancy in rural Kenya: The influence of parity, gestation, and Plasmodium falciparum malaria. Am J Clin Nutr1986;43:803–15.
26.
FlemingAFHendrickseJPAllanNC. The prevention of megaloblastic anaemia in pregnancy in Nigeria. J Obstet Gynaecol Br Commonw1968;75:425–32.
27.
FlemingAF. Haematological manifestations of malaria and other parasitic diseases. Clin Haematol1981;10:983–1011.
28.
StricklandGTKostinasJE. Folic acid deficiency complicating malaria. Am J Trop Med Hyg1970;19:910–5.
29.
BukirwaHGarnerPCritchleyJ. Chlorproguanildapsone for treating uncomplicated malaria. Cochrane Database Syst Rev2004;18:CD004387.
30.
FeroneRBurchallJJHitchingsGH. Plasmodium berghei dihydrofolate reductase. Isolation, properties, and inhibition by antifolates. Mol Pharmacol1969;5:49–59.
31.
PlatzerEG. Dihydrogolate reductase in Plasmodium lophurae and duckling erythrocytes. J Protozool1974;21:400–5.
32.
RolloIM. Antiplasmodial efficacy of 2,4-diaminopyrimidine-sulfonamide combinations, especially against chloroquine-resistant malaria. Can Med Assoc J1975;112(13 spec no):50–3.
33.
ChulayJDWatkinsWMSixsmithDG. Synergistic antimalarial activity of pyrimethamine and sulfadoxine against Plasmodium falciparum in vitro. Am J Trop Med Hyg1984;33:325–30.
34.
HurlyMG. Potentiation of pyrimethamine by sulphadiazine in human malaria. Trans R Soc Trop Med Hyg1959;53:412–3.
35.
WaxmanSHerbertV. Mechanism of pyrimethamine-induced megaloblastosis in human bone marrow. N Engl J Med1969;280:1316–9.
36.
MyattAVHernandezTCoatneyGR. Studies in human malaria. XXXIII. The toxicity of pyrimethamine (daraprim) in man. Am J Trop Med Hyg1953;2:788–94.
37.
HughesAGatusBJ. Severe megaloblastic anaemia caused by maloprim. J Trop Med Hyg1979;82:120–1.
38.
StürchlerDHolzerB. Low serum folate among persons taking Fansidar (pyrimethamine plus sulfadoxine) for prophylaxis of malaria. Acta Trop1980;37:243–8.
39.
FullerNJBatesCJHayesRJBradleyAKGreenwoodAMTullochSGreenwoodBM. The effects of antimalarials and folate supplements on haematological indices and red cell folate levels in Gambian children. Ann Trop Paediatr1988;8:61–7.
40.
PetersonDSWallikerDWellemsTE. Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria. Proc Natl Acad Sci USA1988;85:9114–8.
41.
SibleyCHHydeJESimsPFPloweCVKublinJGMberuEKCowmanAFWinstanleyPAWatkinsWMNzilaAM. Pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: What next?Trends Parasitol2001;17:582–8.
42.
NzilaAMMberuEKSuloJDayoHWinstanleyPASibleyCHWatkinsWM. Towards an understanding of the mechanism of pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: Genotyping of dihydrofolate reductase and dihydropteroate synthase of Kenyan parasites. Antimicrob Agents Chemother2000;44:991–6.
43.
KublinJGDzinjalamalaFKKamwendoDDMalkinEMCorteseJFMartinoLMMukadamRARogersonSJLescanoAGMolyneuxMEWinstanleyPAChimpeniPTaylorTEPloweCV. Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. J Infect Dis2002;185:380–8.
44.
StaedkeSGSendagireHLamolaSKamyaMRDorseyGRosenthalPJ. Relationship between age, molecular markers, and response to sulphadoxine-pyrimethamine treatment in Kampala, Uganda. Trop Med Int Health2004;9:624–9.
45.
ThompsonPEWerbelLM. Antimalarial agents: chemistry and pharmacology. New York: Academic Press, 1972.
46.
KinyanjuiSMMberuEKWinstanleyPAJacobusDPWatkinsWM. The antimalarial triazine WR99210 and the prodrug PS-15: Folate reversal of in vitro activity against Plasmodium falciparum and a non-antifolate mode of action of the prodrug. Am J Trop Med Hyg1999;60:943–7.
47.
CarterJYLoolpapitMPLemaOETomeJLNagelkerkeNJWatkinsWM. Reduction of the efficacy of antifolate antimalarial therapy by folic acid supplementation. Am J Trop Med Hyg2005;73:166–70.
48.
SazawalSBlackRERamsanMChwayaHMStoltzfusRJDuttaADhingraUKaboleIDebSOthmanMKKaboleFM. Effects of routine prophylactic supplementation with iron and folic acid on admission to hospital and mortality in preschool children in a high malaria transmission setting: Community-based, randomised, placebo-controlled trial. Lancet2006;367:133–43.
49.
TielschJMKhatrySKStoltzfusRJKatzJLeClerqSCAdhikariRMullanyLCShrestaSBlackRE. Effect of routine prophylactic supplementation with iron and folic acid on preschool child mortality in southern Nepal: Community-based, cluster-randomised, placebo-controlled trial. Lancet2006;367:144–52.
50.
AbdullaSSchellenbergJANathanRMukasaOMarchantTSmithTTannerMLengelerC. Impact on malaria morbidity of a programme supplying insecticide treated nets in children aged under 2 years in Tanzania: Community cross sectional study. BMJ2001;322:270–3.
51.
MenendezCKahigwaEHirtRVounatsouPAponteJJFontFAcostaCJSchellenbergDMGalindoCMKimarioJUrassaHBrabinBSmithTAKituaAYTannerMAlonsoPL. Randomised placebo-controlled trial of iron supplementation and malaria chemoprophylaxis for prevention of severe anaemia and malaria in Tanzanian infants. Lancet1997;350:844–50.
52.
BrabinBJPremjiZVerhoeffF. An analysis of anemia and child mortality. J Nutr2001;131(2S-2):636S–45S.
53.
ClarkIAChaudhriG. Tumour necrosis factor may contribute to the anaemia of malaria by causing dyserythropoiesis and erythrophagocytosis. Br J Haematol1988;70:99–103.
54.
KurtzhalsJARodriguesOAddaeMCommeyJONkrumahFKHviidL. Reversible suppression of bone marrow response to erythropoietin in Plasmodium falciparum malaria. Br J Haematol1997;97:169–74.
55.
GreenwoodBM. The epidemiology of malaria. Ann Trop Med Parasitol1997;91:763–9.
56.
SnowRWMarshK. The consequences of reducing transmission of Plasmodium falciparum in Africa. Adv Parasitol2002;52:235–64.
57.
PriceRNSimpsonJANostenFLuxemburgerCHkirjaroenLter KuileFChongsuphajaisiddhiTWhiteNJ. Factors contributing to anemia after uncomplicated falciparum malaria. Am J Trop Med Hyg2001;65:614–22.
58.
ShankarAH. Nutritional modulation of malaria morbidity and mortality. J Infect Dis2000;182(suppl 1):S37–53.
59.
OsifoBLChikambaCYSerikiRAdereleWI. Folate levels in protein malnourished Nigerian children. Trop Geogr Med1974;26:379–83.
60.
AkinseteFIBoyoAE. Studies on folic acid in Nigerian infants and pre-school children. J Trop Pediatr Environ Child Health1977;23:202–5.
61.
FlemingAFWerblinskaB. Anaemia in childhood in the guinea savanna of Nigeria. Ann Trop Paediatr1982;2:161–73.
62.
AkenzuaGIIhongbeJCImasuenIW. Haemopoietic response of Nigerian village children to iron, folate supplementation and malaria prophylaxis. J Trop Pediatr1985;31:59–62.
EnglishMSnowRW. Iron and folic acid supplementation and malaria risk. Lancet2006;367:90–1.
65.
BrabinBJ. An analysis of malaria in pregnancy in Africa. Bull World Health Organ1983;61:1005–16.
66.
IsahHSFlemingAFUjahIAEkwempuCC. Anaemia and iron status of pregnant and non-pregnant women in the guinea savanna of Nigeria. Ann Trop Med Parasitol1985;79:485–93.
67.
FlemingAFGhatouraGBHarrisonKABriggsNDDunnDT. The prevention of anaemia in pregnancy in primigravidae in the guinea savanna of Nigeria. Ann Trop Med Parasitol1986;80:211–33.
68.
MatteelliADonatoFSheinAMuchiJALeopardiOAstoriLCarosiG. Malaria and anaemia in pregnant women in urban Zanzibar, Tanzania. Ann Trop Med Parasitol1994;88:475–83.
69.
GailKHermsV. Influence of pteroylglutamic acid (folic acid) on parasite density (Plasmodium falciparum) in pregnant women in West Africa. Z Tropenmed Parasitol1969;20:440–50. (in German)
70.
MbayeARichardsonKBalajoBDunyoSShulmanCMilliganPGreenwoodBWalravenG. Lack of inhibition of the antimalarial action of sulfadoxine-pyrimethamine when used for intermittent preventive treatment in Gambian primigravidae. Am J Trop Med Hyg2006;74:960–4.
71.
NacherMMcGreadyRStepniewskaKChoTLooareesuwanSWhiteNJNostenF. Haematinic treatment of anaemia increases the risk of Plasmodium vivax malaria in pregnancy. Trans R Soc Trop Med Hyg2003;97:273–6.
BaumslagNEdelsteinTMetzJ. Reduction of incidence of prematurity by folic acid supplementation in pregnancy. Br Med J1970;1:16–7.
74.
NostenFMcGreadyRSimpsonJAThwaiKLBalkanSChoTHkirijaroenLLooareesuwanSWhiteNJ. Effects of Plasmodium vivax malaria in pregnancy. Lancet1999;354:546–9.
75.
GuyattHLSnowRW. The epidemiology and burden of Plasmodium falciparum-related anemia among pregnant women in sub-Saharan Africa. Am J Trop Med Hyg2001;64(1–2 suppl):36–44.
76.
DuffyPEFriedM. Malaria in the pregnant woman. Curr Top Microbiol Immunol2005;295:169–200.
77.
van den BroekNRLetskyEA. Etiology of anemia in pregnancy in south Malawi. Am J Clin Nutr2000;72(1 suppl):247S–56S.
